Off-label underdosed apixaban use in Asian patients with non-valvular atrial fibrillation.

So-Ryoung LeeEue-Keun ChoiSang-Hyun ParkJin-Hyung JungKyung-Do HanSeil OhGregory Y H Lip

Published in: European heart journal. Cardiovascular pharmacotherapy (2022)

The off-label underdosed apixaban group showed higher risks of ischaemic stroke, all-cause death, and composite clinical outcomes than the on-label standard dose apixaban group, but both showed comparable risks of MB. Label adherence to apixaban dosing should be emphasized to achieve the best clinical outcomes for Asian patients with AF.

Keyphrases

atrial fibrillation
oral anticoagulants
left atrial
catheter ablation
left atrial appendage
direct oral anticoagulants
venous thromboembolism
heart failure
percutaneous coronary intervention
human health
type diabetes
acute coronary syndrome
coronary artery disease
climate change